Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 47

1.

Short-Course Radiotherapy Followed by Neoadjuvant Bevacizumab, Capecitabine, and Oxaliplatin and Subsequent Radical Treatment in Primary Stage IV Rectal Cancer: Long-Term Results of a Phase II Study.

Bisschop C, van Dijk TH, Beukema JC, Jansen RLH, Gelderblom H, de Jong KP, Rutten HJT, van de Velde CJH, Wiggers T, Havenga K, Hospers GAP.

Ann Surg Oncol. 2017 May 30. doi: 10.1245/s10434-017-5897-0. [Epub ahead of print]

PMID:
28560600
2.

Use of Systemic Therapy Concurrent With Cranial Radiotherapy for Cerebral Metastases of Solid Tumors.

Verduin M, Zindler JD, Martinussen HM, Jansen RL, Croes S, Hendriks LE, Eekers DB, Hoeben A.

Oncologist. 2017 Feb;22(2):222-235. doi: 10.1634/theoncologist.2016-0117. Epub 2017 Feb 6.

PMID:
28167569
3.

Severe fluoropyrimidine toxicity due to novel and rare DPYD missense mutations, deletion and genomic amplification affecting DPD activity and mRNA splicing.

van Kuilenburg AB, Meijer J, Maurer D, Dobritzsch D, Meinsma R, Los M, Knegt LC, Zoetekouw L, Jansen RL, Dezentjé V, van Huis-Tanja LH, van Kampen RJ, Hertz JM, Hennekam RC.

Biochim Biophys Acta. 2017 Mar;1863(3):721-730. doi: 10.1016/j.bbadis.2016.12.010. Epub 2016 Dec 24.

PMID:
28024938
4.

A phase I-II study on the combination of rapamycin and short course radiotherapy in rectal cancer.

Buijsen J, van den Bogaard J, Jutten B, Belgers E, Sosef M, Leijtens JW, Beets GL, Jansen RL, Riedl RG, Clarijs R, Lammering G, Lambin P.

Radiother Oncol. 2015 Aug;116(2):214-20. doi: 10.1016/j.radonc.2015.07.039. Epub 2015 Aug 4.

5.

Neo-adjuvant chemotherapy followed by surgery versus surgery alone in high-risk patients with resectable colorectal liver metastases: the CHARISMA randomized multicenter clinical trial.

Ayez N, van der Stok EP, de Wilt H, Radema SA, van Hillegersberg R, Roumen RM, Vreugdenhil G, Tanis PJ, Punt CJ, Dejong CH, Jansen RL, Verheul HM, de Jong KP, Hospers GA, Klaase JM, Legdeur MC, van Meerten E, Eskens FA, van der Meer N, van der Holt B, Verhoef C, Grünhagen DJ.

BMC Cancer. 2015 Mar 26;15:180. doi: 10.1186/s12885-015-1199-8.

6.

Maintenance treatment with capecitabine and bevacizumab in metastatic colorectal cancer (CAIRO3): a phase 3 randomised controlled trial of the Dutch Colorectal Cancer Group.

Simkens LH, van Tinteren H, May A, ten Tije AJ, Creemers GJ, Loosveld OJ, de Jongh FE, Erdkamp FL, Erjavec Z, van der Torren AM, Tol J, Braun HJ, Nieboer P, van der Hoeven JJ, Haasjes JG, Jansen RL, Wals J, Cats A, Derleyn VA, Honkoop AH, Mol L, Punt CJ, Koopman M.

Lancet. 2015 May 9;385(9980):1843-52. doi: 10.1016/S0140-6736(14)62004-3. Epub 2015 Apr 7.

PMID:
25862517
7.

Effects of five Ayurvedic herbs on locomotor behaviour in a Drosophila melanogaster Parkinson's disease model.

Jansen RL, Brogan B, Whitworth AJ, Okello EJ.

Phytother Res. 2014 Dec;28(12):1789-95. doi: 10.1002/ptr.5199. Epub 2014 Aug 4.

8.

Single-agent bevacizumab or lomustine versus a combination of bevacizumab plus lomustine in patients with recurrent glioblastoma (BELOB trial): a randomised controlled phase 2 trial.

Taal W, Oosterkamp HM, Walenkamp AM, Dubbink HJ, Beerepoot LV, Hanse MC, Buter J, Honkoop AH, Boerman D, de Vos FY, Dinjens WN, Enting RH, Taphoorn MJ, van den Berkmortel FW, Jansen RL, Brandsma D, Bromberg JE, van Heuvel I, Vernhout RM, van der Holt B, van den Bent MJ.

Lancet Oncol. 2014 Aug;15(9):943-53. doi: 10.1016/S1470-2045(14)70314-6. Epub 2014 Jul 15.

PMID:
25035291
9.

Lactate dehydrogenase as a selection criterion for ipilimumab treatment in metastatic melanoma.

Kelderman S, Heemskerk B, van Tinteren H, van den Brom RR, Hospers GA, van den Eertwegh AJ, Kapiteijn EW, de Groot JW, Soetekouw P, Jansen RL, Fiets E, Furness AJ, Renn A, Krzystanek M, Szallasi Z, Lorigan P, Gore ME, Schumacher TN, Haanen JB, Larkin JM, Blank CU.

Cancer Immunol Immunother. 2014 May;63(5):449-58. doi: 10.1007/s00262-014-1528-9. Epub 2014 Mar 8.

PMID:
24609989
10.

Outcomes of extended versus limited indications for patients undergoing a liver resection for colorectal cancer liver metastases.

van Dam RM, Lodewick TM, van den Broek MA, de Jong MC, Greve JW, Jansen RL, Bemelmans MH, Neumann UP, Olde Damink SW, Dejong CH.

HPB (Oxford). 2014 Jun;16(6):550-9. doi: 10.1111/hpb.12181. Epub 2013 Nov 7.

11.

Phase I trial of the combination of the Akt inhibitor nelfinavir and chemoradiation for locally advanced rectal cancer.

Buijsen J, Lammering G, Jansen RL, Beets GL, Wals J, Sosef M, Den Boer MO, Leijtens J, Riedl RG, Theys J, Lambin P.

Radiother Oncol. 2013 May;107(2):184-8. doi: 10.1016/j.radonc.2013.03.023. Epub 2013 May 3.

PMID:
23647753
12.

Ipilimumab in pretreated metastastic uveal melanoma patients. Results of the Dutch Working group on Immunotherapy of Oncology (WIN-O).

Kelderman S, van der Kooij MK, van den Eertwegh AJ, Soetekouw PM, Jansen RL, van den Brom RR, Hospers GA, Haanen JB, Kapiteijn E, Blank CU.

Acta Oncol. 2013 Nov;52(8):1786-8. doi: 10.3109/0284186X.2013.786839. Epub 2013 Apr 23. No abstract available.

PMID:
23607756
13.

Modern multidisciplinary treatment of rectal cancer based on staging with magnetic resonance imaging leads to excellent local control, but distant control remains a challenge.

Engelen SM, Maas M, Lahaye MJ, Leijtens JW, van Berlo CL, Jansen RL, Breukink SO, Dejong CH, van de Velde CJ, Beets-Tan RG, Beets GL.

Eur J Cancer. 2013 Jul;49(10):2311-20. doi: 10.1016/j.ejca.2013.03.006. Epub 2013 Apr 6.

14.

Hyaluronic acid as a marker of hepatic sinusoidal obstruction syndrome secondary to oxaliplatin-based chemotherapy in patients with colorectal liver metastases.

van den Broek MA, Vreuls CP, Winstanley A, Jansen RL, van Bijnen AA, Dello SA, Bemelmans MH, Dejong CH, Driessen A, Olde Damink SW.

Ann Surg Oncol. 2013 May;20(5):1462-9. doi: 10.1245/s10434-013-2915-8. Epub 2013 Mar 6.

PMID:
23463086
15.

Which way is forward in the treatment of rectal cancer?

Jansen RL, Beets GL.

Nat Rev Clin Oncol. 2013 Jan;10(1):12-3. doi: 10.1038/nrclinonc.2012.217. Epub 2012 Dec 11.

PMID:
23229183
16.

Wait-and-see policy for clinical complete responders after chemoradiation for rectal cancer.

Maas M, Beets-Tan RG, Lambregts DM, Lammering G, Nelemans PJ, Engelen SM, van Dam RM, Jansen RL, Sosef M, Leijtens JW, Hulsewé KW, Buijsen J, Beets GL.

J Clin Oncol. 2011 Dec 10;29(35):4633-40. doi: 10.1200/JCO.2011.37.7176. Epub 2011 Nov 7.

PMID:
22067400
17.

MRI after chemoradiotherapy of rectal cancer: a useful tool to select patients for local excision.

Engelen SM, Beets-Tan RG, Lahaye MJ, Lammering G, Jansen RL, van Dam RM, Konsten J, Leijtens JW, van de Velde CJ, Beets GL.

Dis Colon Rectum. 2010 Jul;53(7):979-86. doi: 10.1007/DCR.0b013e3181dc64dc.

PMID:
20551748
18.

HLA-matched allo-SCT after reduced intensity conditioning with fludarabine/CY in patients with metastatic breast cancer.

Fleskens AJ, Lalisang RI, Bos GM, van Gelder M, Jansen RL, Schouten HC.

Bone Marrow Transplant. 2010 Mar;45(3):464-7. doi: 10.1038/bmt.2009.178. Epub 2009 Jul 27.

PMID:
19633692
19.

[Angiogenesis inhibitors for the systemic treatment of metastatic renal cell carcinoma: sunitinib, sorafenib, bevacizumab and temsirolimus].

de Mulder PH, Haanen JB, Sleijfer S, Kruit WH, Gietema JA, Richel DJ, Groenewegen G, Voest EE, van den Eertwegh AJ, Osanto S, Jansen RL, Mulders PF.

Ned Tijdschr Geneeskd. 2008 Feb 16;152(7):371-5. Review. Dutch.

PMID:
18380383
20.

Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial.

Nordlinger B, Sorbye H, Glimelius B, Poston GJ, Schlag PM, Rougier P, Bechstein WO, Primrose JN, Walpole ET, Finch-Jones M, Jaeck D, Mirza D, Parks RW, Collette L, Praet M, Bethe U, Van Cutsem E, Scheithauer W, Gruenberger T; EORTC Gastro-Intestinal Tract Cancer Group; Cancer Research UK; Arbeitsgruppe Lebermetastasen und-tumoren in der Chirurgischen Arbeitsgemeinschaft Onkologie (ALM-CAO); Australasian Gastro-Intestinal Trials Group (AGITG); Fédération Francophone de Cancérologie Digestive (FFCD).

Lancet. 2008 Mar 22;371(9617):1007-16. doi: 10.1016/S0140-6736(08)60455-9.

Supplemental Content

Loading ...
Support Center